Asparcam (Tablets, Solution) Instructions for Use

Instructions
Dosage forms

ATC Code

A12CX (Other mineral substances)

Active Substance

Potassium aspartate and magnesium aspartate (USAN)

Clinical-Pharmacological Group

Drug replenishing potassium and magnesium deficiency in the body

Pharmacotherapeutic Group

Mineral supplements; other mineral supplements; other mineral substances

Pharmacological Action

A source of potassium and magnesium ions. It prevents or eliminates hypokalemia. It improves myocardial metabolism. It improves the tolerability of cardiac glycosides. It has antiarrhythmic activity.

Aspartate transports potassium and magnesium ions and promotes their penetration into the intracellular space. Upon entering the cells, aspartate is included in metabolic processes.

The magnesium ion plays an important role in maintaining the homeostasis of potassium and calcium, has calcium channel blocker properties, and participates in many enzymatic reactions, protein and carbohydrate metabolism.

Pharmacokinetics

Potassium aspartate and magnesium aspartate are intensively absorbed in the intestine, mainly in the small intestine. They are excreted by the kidneys.

Indications

For the elimination of potassium and magnesium deficiency as part of combination therapy for various manifestations of coronary artery disease (including acute myocardial infarction), chronic heart failure, cardiac rhythm disorders (including arrhythmias caused by an overdose of cardiac glycosides).

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
E61.2	Magnesium deficiency
E87.6	Hypokalemia
I20	Angina pectoris
I21	Acute myocardial infarction
I49.9	Cardiac arrhythmia, unspecified
I50.0	Congestive heart failure
T46.0	Poisoning by cardiac glycosides and drugs of similar action

ICD-11 code	Indication
5C64.41	Magnesium deficiency
5C77	Hypokalemia
8D40.2	Myopathy due to nutritional deficiency
BA40.Z	Angina pectoris, unspecified
BA41.Z	Acute myocardial infarction, unspecified
BC64	Sudden arrhythmic death syndrome
BD10	Congestive heart failure
BE2Y	Other specified diseases of the circulatory system
NE60	Poisoning by drugs, medicaments or biological substances, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Determine the dose and regimen individually based on the clinical situation, indication, and chosen dosage form.

Administer tablets orally with a sufficient amount of water.

For intravenous administration, inject slowly as an IV bolus or administer as an IV drip infusion.

Adjust the dosage for patients with chronic renal failure receiving intravenous therapy, ensuring regular monitoring of serum magnesium levels to avoid accumulation.

Monitor for signs of hyperkalemia and hypermagnesemia, especially during rapid intravenous administration.

Use as part of a polarizing mixture with dextrose and insulin to manage cardiac arrhythmias associated with myocardial infarction or digitalis glycoside overdose.

Discontinue treatment if severe adverse reactions, such as high-grade AV block or significant hypotension, occur.

Adverse Reactions

From the digestive system: nausea, vomiting, diarrhea, discomfort or burning in the epigastric region (in patients with anacid gastritis or cholecystitis).

From the cardiovascular system: AV block; with IV administration – a paradoxical reaction in the form of an increase in the number of extrasystoles, decreased blood pressure.

From metabolism: hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnesemia (facial skin hyperemia, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

Local reactions: with IV administration – phlebitis, vein thrombosis.

Contraindications

Hypersensitivity to potassium aspartate and magnesium aspartate; children and adolescents under 18 years of age.

For oral administration: acute and chronic renal failure, hyperkalemia, hypermagnesemia, Addison’s disease, AV block I-III degree, shock, including cardiogenic (BP less than 90 mm Hg), amino acid metabolism disorders, severe myasthenia gravis, hemolysis, acute metabolic acidosis, dehydration.

With caution: pregnancy (especially the first trimester), breastfeeding period.

For intravenous administration: hyperkalemia, hypermagnesemia, acute renal failure, adrenal cortex insufficiency, AV block II and III degree, amino acid metabolism disorders, hemolysis, severe myasthenia gravis, dehydration; Addison’s disease.

With caution: severe liver dysfunction, metabolic acidosis, risk of edema, chronic renal failure – in cases where regular monitoring of serum magnesium levels is impossible (risk of accumulation, toxic magnesium levels), cardiogenic shock (systolic BP less than 90 mm Hg), hypophosphatemia, urolithiasis diathesis associated with impaired metabolism of calcium, magnesium and ammonium phosphate, AV block I degree.

Use in Pregnancy and Lactation

Oral use of this drug during pregnancy (especially the first trimester) is possible only if the potential benefit to the mother outweighs the possible risk to the fetus. Potassium and magnesium aspartate pass into breast milk. If it is necessary to use this drug during lactation, breastfeeding should be discontinued.

Intravenous use of the drug is contraindicated during pregnancy and lactation (breastfeeding).

Use in Hepatic Impairment

Caution should be exercised with intravenous use in patients with severe liver dysfunction.

Use in Renal Impairment

Contraindicated for oral administration in acute and chronic renal failure.

Contraindicated for intravenous administration in acute renal failure. With caution – in chronic renal failure – in cases where regular monitoring of serum magnesium levels is impossible (risk of accumulation, toxic magnesium levels).

Pediatric Use

Contraindicated for use in children and adolescents under 18 years of age.

Special Precautions

Strophanthin or digitalis preparations can be administered together with potassium and magnesium aspartate if necessary.

With rapid intravenous administration, hyperkalemia and hypermagnesemia are possible.

As part of a polarizing mixture (in combination with dextrose and insulin), they normalize the heart rhythm in myocardial infarction, ectopic arrhythmias, and overdose of cardiac glycosides.

Drug Interactions

With simultaneous use with antiarrhythmic drugs, the negative dromotropic and bathmotropic effects of antiarrhythmics are enhanced.

With simultaneous use, beta-blockers, cyclosporine, ACE inhibitors, NSAIDs, potassium-sparing diuretics, salt substitutes containing potassium increase the risk of hyperkalemia.

With simultaneous use with astringent and coating agents, absorption from the gastrointestinal tract is reduced; with anesthetic agents – an increase in the depressant effect on the central nervous system is possible; with atracurium besilate, suxamethonium chloride – an increase in neuromuscular blockade is possible.

With simultaneous use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, ACE inhibitors, NSAIDs, the risk of hyperkalemia increases up to the development of arrhythmia and asystole.

Magnesium reduces the effects of neomycin, polymyxin B, tetracycline, and streptomycin.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Asparcam [Atoll LLC (Russia)]
Tablets 175 mg+175 mg: 10, 20, 30, 40, 50, 56, 60 or 100 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon Pharm, LLC (Russia)

Dosage Form

Asparcam

Tablets 175 mg+175 mg: 10, 20, 30, 40, 50, 56, 60 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a bevel and a score; slight marbling on the surface of the tablets is allowed.

	1 tab.
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: corn starch – 137.5 mg, povidone K25 – 10 mg, magnesium stearate – 2.5 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – jars (1) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.
56 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.

Asparcam [Biosintez, PJSC (Russia)]
Tablets 0.175 g+0.175 g: 10, 20, 30 or 50 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Asparcam

Tablets 0.175 g+0.175 g: 10, 20, 30 or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets white, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Potassium aspartate	0.175 g
Magnesium aspartate	0.175 g

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: corn starch – 0.135 mg, talc – 0.01 mg, calcium stearate – 0.005 g.

Asparcam [Pharmaceutical Company Zdorovye, LLC (Ukraine)]
Tablets 175 mg+175 mg: 50 pcs.

Marketing Authorization Holder

Pharmaceutical Company Zdorovye, LLC (Ukraine)

Dosage Form

Asparcam

Tablets 175 mg+175 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Potassium aspartate	175 mg
Magnesium aspartate	175 mg

10 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – contour cell packs.
50 pcs. – contour cell packs (1) – cardboard packs.

Asparcam [Pharmstandard-Lexredstva OJSC (Russia)]
Tablets 175 mg+175 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Pharmstandard-Lexredstva OJSC (Russia)

Dosage Form

Asparcam

Tablets 175 mg+175 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical, with a bevel and a score.

	1 tab.
Potassium aspartate	175 mg
Magnesium aspartate	175 mg

10 pcs. – contour cell packs.
20 pcs. – contour cell packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – contour cell packs.
50 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Asparcam [YUGPHARM, LLC (Russia)]
Tablets 175 mg+175 mg: 8, 10, 14, 16, 20, 24, 28, 30, 32, 40, 42, 48, 50, 56, 60, 70, 84, or 98 pcs.

Marketing Authorization Holder

YUGPHARM, LLC (Russia)

Dosage Form

Asparcam

Tablets 175 mg+175 mg: 8, 10, 14, 16, 20, 24, 28, 30, 32, 40, 42, 48, 50, 56, 60, 70, 84, or 98 pcs.

Dosage Form, Packaging, and Composition

Tablets white, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: corn starch – 135 mg, talc – 10 mg, calcium stearate – 5 mg.

	1 tab.
Asparcam, semi-finished granules, which contains
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: corn starch – 135 mg, talc – 10 mg, calcium stearate – 5 mg.

8 pcs. – contour cell packs (1) – cardboard packs.
8 pcs. – contour cell packs (2) – cardboard packs.
8 pcs. – contour cell packs (3) – cardboard packs.
8 pcs. – contour cell packs (4) – cardboard packs.
8 pcs. – contour cell packs (5) – cardboard packs.
8 pcs. – contour cell packs (6) – cardboard packs.
8 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
14 pcs. – contour cell packs (1) – cardboard packs.
14 pcs. – contour cell packs (2) – cardboard packs.
14 pcs. – contour cell packs (3) – cardboard packs.
14 pcs. – contour cell packs (4) – cardboard packs.
14 pcs. – contour cell packs (5) – cardboard packs.
14 pcs. – contour cell packs (6) – cardboard packs.
14 pcs. – contour cell packs (7) – cardboard packs.

Asparcam Medisorb [Medisorb, JSC (Russia)]
Tablets 175 mg+175 mg: from 7 to 120 pcs.

Marketing Authorization Holder

Medisorb, JSC (Russia)

Dosage Form

Asparcam Medisorb

Tablets 175 mg+175 mg: from 7 to 120 pcs.

Dosage Form, Packaging, and Composition

Tablets white, round, flat-cylindrical, with a bevel on both sides and a score on one side.

	1 tab.
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: potato starch, colloidal silicon dioxide (aerosil), macrogol 6000 (polyethylene glycol), calcium stearate.

From 7 to 14 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
From 20 to 120 pcs. – jars (1) – cardboard packs.

Asparcam-Farmak [Farmak, JSC (Ukraine)]
Solution for intravenous administration 45.2 mg+40 mg/1 ml: amp. 5 ml, 10 ml or 20 ml 10 pcs.

Marketing Authorization Holder

Farmak, JSC (Ukraine)

Dosage Form

Asparcam-Farmak

Solution for intravenous administration 45.2 mg+40 mg/1 ml: amp. 5 ml, 10 ml or 20 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or slightly yellowish.

	1 ml
Potassium aspartate anhydrous*	45.2 mg,
Which corresponds to potassium content	10.33 mg
Magnesium aspartate anhydrous*	40 mg,
Which corresponds to magnesium content	3.37 mg

* obtained according to the formulation: aspartic acid – 72.05 mg, heavy magnesium oxide (calculated as 100% substance) – 5.59 mg, potassium hydroxide (calculated as 100% substance) – 14.82 mg.

Excipients: sorbitol – 50 mg, water for injection – up to 1 ml.

5 ml – ampoules (5) – blisters (2) – cardboard packs.
10 ml – ampoules (5) – blisters (2) – cardboard packs.
20 ml – ampoules (5) – blisters (2) – cardboard packs.
5 ml – ampoules (10) – cardboard packs with inserts.
10 ml – ampoules (10) – cardboard packs with inserts.
20 ml – ampoules (10) – cardboard packs with inserts.

Asparcam-Ferein [Bryntsalov-A, JSC (Russia)]
Solution for intravenous administration 45.2 g+40 g/1 l: amp. 5 ml 10 pcs.

Marketing Authorization Holder

Bryntsalov-A, JSC (Russia)

Dosage Form

Asparcam-Ferein

Solution for intravenous administration 45.2 g+40 g/1 l: amp. 5 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 l
Potassium aspartate	45.2 g*
Equiv. 10.33 g potassium
Magnesium aspartate	40 g*
Equiv. 3.37 g magnesium

* – obtained according to the formulation: aspartic acid 74 g, magnesium oxide 5.59 g, potassium hydroxide 14.82 g in 1 l of solution.

5 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.

Asparcam-L [Biosintez, PJSC (Russia)]
Solution for infusion 11.59 mg+7.88 mg/1 ml: bot. 200 ml 1 or 24 pcs., bot. 400 ml 1 or 12 pcs., containers 250 ml 1 or 24 pcs., containers 500 ml 1 or 12 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Asparcam-L

Solution for infusion 11.59 mg+7.88 mg/1 ml: bot. 200 ml 1 or 24 pcs., bot. 400 ml 1 or 12 pcs., containers 250 ml 1 or 24 pcs., containers 500 ml 1 or 12 pcs.

Dosage Form, Packaging, and Composition

Solution for infusion as a transparent, colorless or slightly colored liquid.

	1 ml
Potassium L-aspartate*	11.59 mg,
Incl. potassium ions	2.65 mg
Magnesium L-aspartate*	7.88 mg,
Incl. magnesium ions	0.66 mg

* formed as a result of the interaction of L-aspartic acid, magnesium oxide, potassium hydroxide.

Excipients: sorbitol (sorbitol), water for injection.

200 ml – glass bottles for blood (1) – cardboard packs.
200 ml – glass bottles for blood (24) – cardboard boxes.
400 ml – glass bottles for blood (1) – cardboard packs.
400 ml – glass bottles for blood (12) – cardboard boxes.
250 ml – polymer containers (1) – film bags (1) – cardboard packs.
500 ml – polymer containers (1) – film bags (1) – cardboard packs.
250 ml – polymer containers (24) – cardboard boxes.
500 ml – polymer containers (12) – cardboard boxes.

Asparcam-L [Biosintez, PJSC (Russia)]
Solution for intravenous administration 45.2 g+40 g/1 L: amp. 5 mL or 10 mL 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Asparcam-L

Solution for intravenous administration 45.2 g+40 g/1 L: amp. 5 mL or 10 mL 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 l
Potassium aspartate	45.2 g*
Equiv. potassium	10.33 g
Magnesium aspartate	40 g*
Equiv. magnesium	3.37 g

* – obtained according to the formulation: aspartic acid 74 g, magnesium oxide 5.59 g, potassium hydroxide 14.82 g in 1 l of solution.

5 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.
10 ml – ampoules (10) – cardboard packs.

Asparcam-UBF [Uralbiopharm, JSC (Russia)]
Tablets 175 mg+175 mg: 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.

Marketing Authorization Holder

Uralbiopharm, JSC (Russia)

Dosage Form

Asparcam-UBF

Tablets 175 mg+175 mg: 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white, round, flat-cylindrical shape, with a score and a bevel.

	1 tab.
Potassium aspartate hemihydrate	175 mg
Magnesium aspartate tetrahydrate	175 mg

Excipients: potato starch, povidone K17, talc, calcium stearate.

10 pcs. – non-cell contour packs (1) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
25 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
70 pcs. – polymer jars (1) – cardboard packs.
80 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Medixlife (Author)

View all posts Profile link